Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population

Clinical Endocrinology

Volumn 64, Issue 6, 2006, Pages 652-658

  Gannagé Yared, Marie Hélène ^a,c   Fares, Florence ^a   Semaan, Michelle ^a   Khalife, Simon ^b   Jambart, Selim ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANDROGEN; CHOLESTEROL; ESTRADIOL; GLUCOSE; GROWTH HORMONE; INSULIN; LEPTIN; LIPID; OSTEOPROTEGERIN; PRASTERONE SULFATE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TESTOSTERONE;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; BODY MASS; CALCULATION; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; AGED; BIOLOGICAL MARKERS; CORONARY DISEASE; GLYCOPROTEINS; GONADAL STEROID HORMONES; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REGRESSION ANALYSIS;

EID: 33646824551     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02522.x     Document Type: Article

References (39)

1. Simonet, W.S., Lacey, D.L., Dunstan, C.R., Kelley, M., Chang, M.S., Luthy, R., Nguyen, H.Q., Wooden, S., Bennet, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H.L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T.M., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R. Boyle, W.J. 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89, 309 319.
2. Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y.X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. Boyle, W.J. 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93, 165 176.
3. Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S., Gombibucji, T., Yano, K., Shima, N., Washida, N., Tsuda, E., Morinaga, T., Higashio, K. Ozawa, H. 1998 Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochemistry and Biophysics Research Communications, 247, 610 615.
4. Bucay, N., Sarosi, I., Dunstan, C.R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H.L., Xu, W., Lacey, D.L., Boyle, W.J. Simonet, W.S. 1998 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development, 12, 1260 1268.
5. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N. Suda, T. 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences USA, 95, 3597 3602.
6. Hofbauer, L.C. Heufelder, A.E. 2000 The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. Journal of Clinical Endocrinology and Metabolism, 85, 2355 2363.
7. Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T. Higashio, K. 1997 Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochemistry and Biophysics Research Communications, 234, 137 142.
8. Kwon, B.S., Wang, S., Udagawa, N., Haridas, V., Lee, Z.H., Kim, K.K., Oh, K.O., Greene, J., Li, Y., Su, J., Gentz, R., Aggarwal, B.B. Ni, J. 1998 TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits asteoclastogenesis and bone resorption. FASEB Journal, 12, 845 854.
9. Kong, Y.Y., Yoshida, H., Sarosi, I., Tan, H.L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A.J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C.R., Lacey, D.L., Mak, T.W., Boyle, W.J. Penninger, J.M. 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397, 315 323.
10. Koshla, S. 2001 Minireview: The OPG/RANKL/RANK system. Endocrinology, 12, 1260 1268.
11. Hofbauer, L.C., Shui, C., Riggs, B.L., Dunstan, C.R., Spelsberg, T.C., O'Brien, T. Khosla, S. 2001 Effects of immunosuppressants on receptor activator of NF-B ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochemistry and Biophysics Research Communications, 280, 334 339.
12. Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W. Osdoby, P. 2001 Receptor activator of NF-B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. Journal of Biological Chemistry, 276, 20659 20672.
13. Schoppet, M., Preissner, K.T. Hofbauer, L.C. 2002 RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 549 553.
14. Min, H., Morony, S., Sarosi, I., Dunstan, C.R., Capparelli, C., Van Scully, S.G., Van, G., Kaufman, S., Kostenuik, P.J., Lucey, D.L., Boyle, W.J. Simonet, W.S. 2000 Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. Journal of Experimental Medicine, 192, 463 474.
15. Browner, W.S., Lui, L.Y. Cummings, S.R. 2001 Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. Journal of Clinical Endocrinology and Metabolism, 86, 631 637.
16. Kiechl, S., Schett, G., Wenning, G., Redlich, K., Oberhollenzer, M., Mayr, A., Santer, P., Smolen, J., Poewe, W. Willeit, J. 2004 Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation, 109, 2175 2180.
17. Schoppet, M., Sattler, A.M. Schaefer, J.R. 2003 Increased osteoprotegerin serum levels in men with coronary artery disease. Journal of Clinical Endocrinology and Metabolism, 88, 1024 1028.
18. Rhee, E.J., Lee, W.Y., Kim, S.Y., Kim, B.J., Sung, K.C., Kim, B.S., Kang, J.H., Oh, K.W., Oh, E.S., Baek, K.H., Kang, M.I., Woo, H.Y., Park, H.S., Kim, S.W., Lee, M.H. Park, C.Y. 2005 Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clinical Science, 108, 237 243.
19. Jono, S., Ikari, Y., Shioi, A., Mori, K., Miki, T., Hara, K. Nishizawa, Y. 2002 Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation, 106, 1192 1194.
20. Avignon, A., Sultan, A., Piot, C., Elaerets, S., Cristol, J.P. Dupuy, A.M. 2005 Osteoprotegerin is associated with silent coronary artery disease in high risk asymptomatic type 2 diabetic patients. Diabetes Care, 28, 2176 2180.
21. Knudsen, S.T., Foss, C.H., Poulsen, N.H., Andersen, C.E., Mogensen, L.M. Rasmussen, L.M. 2003 Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. European Journal of Endocrinology, 149, 39 42.
22. Oh, E.S., Rhee, E.J., Oh, K.W., Lee, W.Y., Baek, K.H., Yoon, K.H., Kang, J.H., Yun, E.J., Park, C.Y., Choi, M.G., Yoo, H.J. Park, S.W. 2005 Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low density lipoprotein cholesterol levels in healthy Korean women. Metabolism, 54, 49 54.
23. Ugur-Altun, B., Altun, A., Gerenli, M. Tugrul, A. 2005 The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. Diabetes Research and Clinical Practice, 68, 217 222.
24. Pittas, A.G., Joseph, N.A. Greenberg, A.S. 2004 Adipocytokines and insulin resistance. Journal of Clinical Endocrinology and Metabolism, 89, 447 452.
25. Khosla, S., Arrighi, H.M., Melton, L.J. Atkinson, E.J., O'Fallon, W.M., Dunstan, C. Riggs, B.L. 2002 Correlates of osteoprotegerin levels in women and men. Osteoporosis International, 13, 394 399.
26. Rogers, A., Saleh, G., Hannon, R.A., Greenfield, D. Eastell, R. 2002 Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 87, 4470 4475.
27. Szulc, P., Hofbauer, L.C., Heufelder, A.E., Roth, S. Delmas, P.D. 2001 Osteoprotegerin serum in men: correlation with age, Estrogen, and testosterone status. Journal of Clinical Endocrinology and Metabolism, 86, 3162 3165.
28. Rubin, J., Ackert-Bicknell, C.L., Zhu, L., Fan, X., Murphy, T.C., Nanes, M.S., Marcus, R., Holloway, L., Beamer, W.G. Rosen, C.J. 2002 IGF-1 regulates osteoprotegerin and receptor activator of nuclear factor-κB ligand in vitro and OPG in vivo. Journal of Clinical Endocrinology and Metabolism, 87, 4273 4279.
29. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of high blood cholesterol in Adults. (Adult Treatment Panel III final report) ( 2002 Circulation, 106, 3413 3421.
30. Katz, A., Nambi, S.S., Mather, K., Baron, A.D., Follmann, D.A., Sullivan, G. Quon, A. 2000 Quantitative insulin sensitivity check index. A sample method for assessing insulin sensitivity. Journal of Clinical Endocrinology and Metabolism, 85, 2402 2410.
31. Sattler, A.M., Schoppet, M., Schaefer, L.C. Hofbauer, L.C. 2004 Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcified Tissue International, 74, 103 106.
32. Misra, M., Soyka, L.A., Miller, K.K., Herzog, D.B., Grinspoon, S., De Chen, D., Neubauer, G. Klibanski, A. 2003 Serum osteoprotegerin in adolescent girls with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism, 88, 3816 3822.
33. Xydakis, A.M., Case, C.C., Jones, P.H., Hoogeveen, R.C., Liu, M.Y., Smith, E.O., Nelson, K.W. Ballantyne, C.M. 2004 Adiponectin, inflammation and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. Journal of Clinical Endocrinology and Metabolism, 89, 2697 2703.
34. Spranger, J., Kroke, A., Mohlig, M., Bergmann, M.M., Ristow, M., Boeing, H. Pfeiffer, A.F. 2003 Adiponectin and protection against type 2 diabetes mellitus. Lancet, 361, 226 228.
35. Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K. Yamada, Y. 1999 Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. Journal of Bone Mineral Research, 14, 518 527.
36. Hofbauer, L.C., Hicok, K.C., Chen, D. Khosla, S. 2002 Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. European Journal of Endocrinology, 147, 269 273.
37. Khosla, S., Atkinson, E.J., Dunstan, E.J. O'Fallon, W.M. 2002 Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. Journal of Clinical Endocrinology and Metabolism, 87, 1550 1554.
38. Hofbauer, L.C., Khosla, S., Dunstan, C.R., Lacey, D.L., Spelsberg, T.C. Riggs, B.L. 1999 Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology, 140, 4367 4370.
39. Saika, M., Inoue, D., Kido, S. Matsumoto, T. 2001 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology, 142, 2205 2212.